Short Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Grows By 43.9%

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 136,100 shares, a growth of 43.9% from the August 31st total of 94,600 shares. Based on an average daily trading volume, of 73,500 shares, the short-interest ratio is presently 1.9 days.

Enlivex Therapeutics Price Performance

ENLV stock traded up $0.06 during mid-day trading on Friday, reaching $1.64. The company had a trading volume of 196,610 shares, compared to its average volume of 136,267. The company has a market capitalization of $35.11 million, a PE ratio of -1.18 and a beta of 1.03. The firm has a 50 day moving average of $1.34 and a 200 day moving average of $1.77. Enlivex Therapeutics has a 12 month low of $1.15 and a 12 month high of $4.59.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its earnings results on Friday, August 30th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. Analysts anticipate that Enlivex Therapeutics will post -0.7 EPS for the current year.

Analyst Ratings Changes

ENLV has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Enlivex Therapeutics in a report on Friday. EF Hutton Acquisition Co. I raised shares of Enlivex Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 27th.

Institutional Trading of Enlivex Therapeutics

A hedge fund recently bought a new stake in Enlivex Therapeutics stock. XTX Topco Ltd bought a new position in shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 24,820 shares of the company’s stock, valued at approximately $35,000. XTX Topco Ltd owned 0.12% of Enlivex Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.